Creative Biolabs has expanded its advanced single-cell multi-omics and RNA sequencing solutions, aiming to support biomedical discovery by meeting the growing demand for high-resolution cellular profiling. The upgraded suite, announced on September 9, 2026, offers end-to-end services ranging from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, serving researchers in oncology, immunology, and neuroscience.
The shift from bulk tissue profiling to single-cell resolution has made it essential to dissect cellular heterogeneity, identify rare cell subpopulations, characterize complex tumor microenvironments, and trace cell lineage trajectories. To address these needs, Creative Biolabs provides robust, high-throughput single-cell RNA sequencing services that deliver high sensitivity and coverage across thousands of individual cells, yielding high-resolution transcriptomic insights from diverse fresh biological specimens.
The platform also features specialized single-nucleus RNA sequencing (snRNA-seq) capabilities to overcome the long-standing challenge of processing complex, fibrous, or biobanked archival samples. For tissues where single-cell dissociation can cause cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs offers an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation while minimizing dissociation-related artifacts and retaining informative nuclear RNA profiles, thereby expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs has advanced its high-throughput single-cell multi-omics service. This integrated platform allows simultaneous interrogation of genomic variations, epigenomic landscapes such as chromatin accessibility, cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease. For more information about Creative Biolabs and its full suite of single-cell analytical solutions, visit https://singlecell.creative-biolabs.com/.
The expansion matters because it addresses a critical bottleneck in biomedical research: the ability to analyze challenging samples at single-cell resolution. By enabling researchers to study rare cell types, complex tissues, and archived clinical specimens with greater accuracy, these services could accelerate the development of precision medicines and biomarkers. For the pharmaceutical and biotechnology industries, this means more reliable target validation and deeper insights into disease mechanisms, potentially shortening drug development timelines. Ultimately, patients may benefit from therapies tailored to the specific cellular and molecular profiles of their diseases.
